In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Natasa DjurdjevicClinic for Pulmonology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.ORCID 0000-0002-0825-4748 Marija Dusanović PjevicInstitute of Human Genetics, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0002-3564-2623 Mihailo StjepanovicClinic for Pulmonology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.ORCID 0000-0003-1787-1438 Sanja Dimic-JanjicClinic for Pulmonology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.ORCID 0000-0001-9989-3862 Jelena JankovicClinic for Pulmonology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.ORCID 0000-0001-8529-8624 Andrej ZecevicClinic for Pulmonology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.
Milica TerzicClinic for Allergology and Immunology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.ORCID 0009-0006-6837-5222 Aleksa GolubovicClinic for Pulmonology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.ORCID 0009-0004-2848-6521 Ivan MilivojevicClinic for Pulmonology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.ORCID 0000-0002-3289-8148 Snjezana MijatovicClinic for Pulmonology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.ORCID 0009-0005-1807-4571 Milka GrkInstitute of Human Genetics, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0002-7534-9608 Funding
Ministry of Science, Technological Development, and Innovation 451-03-66/2024-03/200110
6 · The paper itselfAbstract
Progressive pulmonary fibrosis (PPF) comprises interstitial lung diseases characterized by progressive fibrosis and lung function decline. Nintedanib slows disease progression by inhibiting FGFR, VEGFR, and PDGFR signaling, but treatment response varies among patients. We investigated whether
Indexed as
IndolesPolymorphism, Single NucleotidePulmonary FibrosisReceptor, Platelet-Derived Growth Factor betaTransforming Growth Factor beta1Vascular Endothelial Growth Factor Receptor-2AgedDisease ProgressionFemaleGenotypeHumansMaleMiddle AgedProspective StudiesTreatment OutcomeIndolesKDR protein, humannintedanibReceptor, Platelet-Derived Growth Factor betaTGFB1 protein, humanTransforming Growth Factor beta1Vascular Endothelial Growth Factor Receptor-2adverse effectsnintedanibPDGFRBpharmacogeneticspolymorphismsprogressive pulmonary fibrosisTGFB1VEGFR2
Identifiers
PMID42737450
PMCPMC13565948
What OpenQuestion holds
Textmetadata
Read underepoch 390